Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.
Solid Tumors
DRUG: Tomivosertib (eFT-508)
Proportion of subjects with treatment-emergent AEs (TEAEs) and serious AEs (SAEs), The incidence of TEAEs and SAEs will be summarized and TEAEs will also be summarized by severity and according to their relationship to Tomivosertib (eFT-508)., 52 weeks|Overall Response Rate (ORR) as determined by RECIST 1.1, Defined as the proportion of subjects who achieve a best overall response of complete response (CR) or partial response (PR)., 52 weeks|Progression Free Survival (PFS) as determined by RECIST 1.1, Defined as the interval from the start of Tomivosertib (eFT-508) to the occurrence of PD or death from any cause., 52 weeks
ORR as determined by iRECIST, Defined as the proportion of subjects who achieve a best overall response of CR assigned using iRECIST (iCR) or PR assigned using iRECIST (iPR)., 52 weeks|PFS as determined by iRECIST, Defined as the interval from the start of Tomivosertib (eFT-508) to the occurrence of confirmed progression assigned using iRECIST (iCPD) or death from any cause., 52 weeks|Overall survival, Defined as time from the first dose date of Tomivosertib (eFT-508) to death due to any cause will be summarized., 52 weeks
This Phase 2, open-label study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of Tomivosertib (eFT-508) in subjects who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of partial response (PR) or complete response (CR).